For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 1,060,191 | |||
| General and administrative | 2,174,751 | |||
| Total operating expenses | 3,234,942 | |||
| Loss from operations | -3,234,942 | |||
| Change in fair value of warrant liability | -3,967 | |||
| Interest income | 121,984 | |||
| Total other income | 125,951 | |||
| Net loss | -3,108,991 | |||
| Net loss attributable to common stockholders | -3,108,991 | |||
| Basic EPS | -2.65 | |||
| Diluted EPS | -2.65 | |||
| Basic Average Shares | 1,174,869 | |||
| Diluted Average Shares | 1,174,869 | |||
Bone Biologics Corp (BBLG)
Bone Biologics Corp (BBLG)